Entolimod, an Adjuvant for Vaccine Augmentation

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 8, 2017

Primary Completion Date

March 9, 2018

Study Completion Date

December 31, 2019

Conditions
Substance Use Disorders
Interventions
DRUG

Entolimod

The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).

BIOLOGICAL

Td Vaccine

The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).

Trial Locations (1)

77030

Baylor College of Medicine, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER

NCT03063736 - Entolimod, an Adjuvant for Vaccine Augmentation | Biotech Hunter | Biotech Hunter